Get Retatrutide Online in Maryland | OmniRx Health
Medical Weight Loss Treatment in Maryland
Retatrutide (LY3437943) is a 39-amino acid synthetic peptide and triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Currently in Phase 3 clinical trials (TRIUMPH program), it produced 24.2% average weight loss at 48 weeks in Phase 2 data — the highest weight reduction observed in any peptide trial to date. Listed by OmniRx for research-use only (RUO).
Key Benefits
- Triple receptor mechanism: GLP-1 + GIP + glucagon for amplified metabolic effect
- Phase 2 data shows 24.2% average weight loss at 48 weeks (12mg dose)
- ~58% hepatic fat reduction in Phase 2 sub-group analyses
- Elevated basal metabolic rate via glucagon receptor agonism
- Research-grade purity ≥98% with full CoA, HPLC, and MS documentation
Who is a Good Candidate?
Intended for laboratory researchers and pre-clinical study investigators studying triple receptor agonism, obesity mechanisms, hepatic metabolism, or GLP/GIP/glucagon signaling pathways. Listed for research-use only (RUO) — not for human therapeutic use.
Available for research use
Serving Maryland
Maryland bridges the nation's capital with the Chesapeake Bay's natural beauty. OmniRx Health serves this diverse state—from the federal workers of Montgomery County to the waterfront communities of the Eastern Shore, the professionals of Baltimore's Inner Harbor to the rural areas of Western Maryland. Our telehealth platform is perfect for busy Marylanders who want world-class care without the notorious DC-area traffic.
Our providers are licensed by the Maryland Board of Physicians to deliver telehealth services throughout the state.
Maryland's extensive pharmacy network in Baltimore, DC suburbs, and throughout the state ensures rapid prescription access and delivery.
Maryland has comprehensive telehealth laws that balance innovation with patient protection, supporting virtual care across the state.
Maryland mandates telehealth coverage parity, requiring insurers to cover virtual visits at the same rate as in-person appointments.
Frequently Asked Questions
- What is retatrutide and how does it work?
- Retatrutide (CAS 2381089-83-2) is a 39-amino acid synthetic peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. This triple agonism produces coordinated appetite suppression (GLP-1), amplified insulin and fat-cell metabolism (GIP), and increased hepatic glucose output and resting energy expenditure (glucagon). It is currently in Phase 3 clinical trials and is available for research-use only (RUO).
- How does retatrutide compare to semaglutide and tirzepatide in research?
- Phase 2 data (NEJM, 2023) showed retatrutide at 12mg produced 24.2% average weight loss at 48 weeks, outperforming semaglutide (~15% at 68 weeks) and tirzepatide (~22% at 72 weeks) in their respective trials. Retatrutide adds glucagon receptor agonism — absent in both comparators — which appears to drive additional metabolic rate elevation and hepatic fat clearance.
- Is retatrutide available for human use?
- No. Retatrutide has not received FDA approval for any human therapeutic use. It is currently in Phase 3 (TRIUMPH) clinical trials and is listed by OmniRx strictly as a research-use only (RUO) compound for laboratory and pre-clinical research applications.
- Is telehealth legal in Maryland?
- Yes, telehealth is fully legal in Maryland with comprehensive regulations supporting virtual healthcare delivery. Licensed providers can offer consultations, prescriptions, and ongoing care management.
- Can DC commuters in Maryland use telehealth?
- Telehealth is perfect for Maryland's DC commuters. Skip the traffic and get care from home, whether you're in Bethesda, Silver Spring, or Columbia.
- Does Maryland insurance cover telehealth?
- Yes, Maryland requires insurance companies to cover telehealth services at parity with in-person visits. Most commercial plans and Medicaid cover virtual consultations.